Feasibility of Implementing a Pharmacist-Integrated Collaborative Model for Opioid Use Disorder: A Nonrandomized Clinical Trial - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessing the Feasibility of a Pharmacist-Integrated Collaborative Care Model for Opioid Use Disorder: A Nonrandomized Clinical Trial

  • By

  • Felicity Homsted

  • David A. Fiellin

  • Udi E. Ghitza

  • Vernon T. Gardner

  • Bethany McLeman

  • Paul J. Joudrey

  • Gerald Cochran

  • Sarah K. Moore

  • Lisa Saldana

  • Edward Chongsi

  • Kimberly Kramer

  • Ashley Vena

  • Rebecca A. Ottesen

  • Jacklyn Harris

  • Jesse S. Boggis

  • Deepika Rao

  • Owen Murray

  • Scott Gerlach

  • Phoebe Gauthier

  • Katie P. Osterhage

  • Laura-Mae Baldwin

  • Lisa A. Marsch

  • October 14, 2026

Share

Original Source(s)

Feasibility of Implementing a Pharmacist-Integrated Collaborative Model for Opioid Use Disorder: A Nonrandomized Clinical Trial

  • by Felicity Homsted, David A. Fiellin, Udi E. Ghitza, Vernon T. Gardner, Bethany McLeman, Paul J. Joudrey, Gerald Cochran, Sarah K. Moore, Lisa Saldana, Edward Chongsi, Kimberly Kramer, Ashley Vena, Rebecca A. Ottesen, Jacklyn Harris, Jesse S. Boggis, Deepika Rao, Owen Murray, Scott Gerlach, Phoebe Gauthier, Katie P. Osterhage, Laura-Mae Baldwin, Lisa A. Marsch

  • October 14, 2026

Related Content

When Employment Structures Define Professionalism in General Internal Medicine

FDA approves first therapy for symptomatic dermographism

The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.

Correction: Telehealth Use and Modality Choice Among US Adults: Shorrocks-Shapley Decomposition of a 2022 Cross-Sectional National Survey